Q: How do Roche’s diagnostic tests and medicines, particularly those for cancer, contribute to personalized healthcare and empower healthcare professionals?
A: By prioritizing genetic testing, Roche enables patients to identify the specific type of cancer they have. This knowledge is crucial to create personalized treatment plans, moving away from generic approaches like traditional chemotherapy. Genetic testing allows healthcare professionals to tailor therapies based on the unique genetic makeup of each patient’s cancer. For example, Roche’s diagnostic tests help identify the numerous subtypes of lung cancer, enabling the use of directed therapies designed for specific subtypes and greatly improving the chances of a successful treatment.
Roche’s commitment to staying at the forefront of scientific advances ensures the generation of diagnostic tests that empower healthcare professionals, giving them the information needed for targeted and effective interventions. Our focus on personalized medicine contributes to improved patient outcomes and elevated standards of care.
Q: How does Roche’s emphasis on scientific innovation align with the company’s goal to positively influence socio-economic outcomes?
A: Roche is renowned for its commitment to healthcare R&D, focusing on innovation to tackle prevalent health challenges globally. In response to Mexico’s evolving healthcare landscape, the company strategically invests in areas reflective of shifting disease burdens, emphasizing cancer, cardiovascular diseases, obesity, diabetes, and emerging trends like neurological disorders. For example, the company focuses on hemophilia therapy, as the ability to prevent bleeding not only influences immediate medical outcomes but also carries substantial socio-economic implications. A patient with severe hemophilia may face educational barriers as schools may be ill-equipped to handle potential emergencies, contributing to societal disruption. Moreover, caregivers may be constrained in their ability to work due to the need for constant vigilance. Roche sees beyond direct medication costs, acknowledging the profound economic benefits tied to enabling patients to lead more normalized lives, allowing them to return to school or the workforce and ultimately fostering societal reintegration.
Roche views supporting scientific research as pivotal, not only for advancing medical progress but also for driving positive transformations in communities. This approach aligns seamlessly with the company’s commitment to addressing health challenges comprehensively in Mexico and the world.
Q: How is Roche helping to change the public perception of healthcare from an expenditure to an investment? What public policies does Mexico need to further this goal?
A: Aligning with global recommendations, Roche underscores the need for increased public healthcare spending in Mexico, as the country’s healthcare budget is below the WHO-recommended 6% of GDP. We advocate for viewing health as a strategic investment, as economic rationales indicate a potential return of US$4 for every dollar invested in healthcare, primarily through productivity gains.
To address concerns about wastage in the healthcare system, we champion the adoption of digital health solutions. By empowering individuals through digital health records on their smartphones it is possible to reduce redundancy in medical tests and enhance overall efficiency. Roche actively participates in the Health Movement, a foundation co-founded with partners such as Microsoft and Siemens Healthineers. Together, we aim to showcase the feasibility of transforming and optimizing health systems through digital means. By engaging in such partnerships and piloting solutions, we contribute to shifting the perception of health from an expense to a strategic investment in Mexico and abroad.
Q: What are Roche’s strategic priorities for the Mexican market and the broader Latin American region in the coming year?
A: Our key strategic priorities for Mexico and Latin America revolve around ensuring the effective delivery of our innovations to patients in need. Our focus goes beyond clinical trials, emphasizing a tangible impact on people’s lives. We are committed to contributing to the sustainability of health systems, particularly in light of the growth of the elderly population and the prevalence of chronic diseases. Roche actively seeks to enhance the efficiency of healthcare systems, addressing the evolving healthcare needs of the region.
Beyond addressing anticipated health challenges, we actively contribute to the creation of resilient healthcare systems tailored to the region’s unique needs. At the core of our commitment is ensuring groundbreaking medical advances effectively reach patients. In Latin America, we aspire to be a reliable partner, leaving no patient behind in our pursuit of a healthier future.
Roche is a global pioneer in pharmaceuticals and diagnostics with over 125 years of experience in the development and supply of treatments for major diseases.